Carol Giltner Gallagher

Carol Giltner Gallagher (board member) discloses dealings in 3 companies, chiefly Atara Biotherapeutics, Inc., Mirati Therapeutics, Inc. and Certara, Inc. In total, 10 filings cover trades dated from 8 June 2021 to 10 June 2025.

The open-market record is one-sided, with 1 purchase worth €37k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 8 share grants.

The latest filing, published on 12 June 2025, reports a share grant in Atara Biotherapeutics, Inc. The clock since the last published purchase (15 November 2023) now reads 1,068 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.